ASX Insider Trades: Directors bought and sold these 6 stocks last week

Welcome back to the Insider Trades series – a weekly summary of on-market ASX 200 director transactions valued at more than $10,000. The below trades have all taken place between 31 October and 4 November 2025. Directors have up to 5 business days to notify the ASX of their trades.

The volume of transaction has slowed down in recent weeks, so this week's data will feature a few sub-$1 billion market cap trades of interest.

Top ASX 200 Insider Buys

Interesting takeaways

Healius CEO Paul Anderson has been in the role since March 2024 and bought shares for the second time, more than doubling his stake to 95,308 shares. The stock experienced extreme volatility during reporting season after its FY25 result came in below consensus for revenue and EBIT, though the underlying NPAT loss was better than feared. This still triggered a sharp 13.5% selloff on 21 August, sending the stock to its lowest level since 2003. The stock then rallied 37% over the next four sessions, with The Australian speculating that M&A might again be in focus. Another article in early October reported that while no bid was imminent, Bain's name had come up in deal-making conversations. The stock has found some stability in recent weeks and is up 12% since the FY25 result. The company still faces considerable challenges including: changes to Medicare eligibility for Vitamin B12 and urine testing implemented on 1 July 2025, which led to modest decreases in test volumes, and increased competition from smaller players like 4Cyte, which has cited growing collection rates.

Healius year-to-date price chart (Source: TradingView)

All other transactions have been made by Non-Executive Directors.

Top ASX 200 Insider Sells

Interesting takeaways

No large cap director transactions appeared over the 31 October to 4 November period. Qoria is an interesting case, with three large insider selldowns occurring while the stock has rallied 47% year-to-date (the peak YTD return was 91%) and trades around the $1 billion market cap level.

Qoria price chart (Source: TradingView)

Qoria is a global provider of cyber safety products and services, primarily targeting students from kindergarten to year 12. The company takes an ecosystem-based approach where its offerings can be delivered across any network and device, and allows other providers to embed Qoria's products and services into their own offerings.

The story centres on growing annual recurring revenue (ARR), which has expanded from $7 million in FY20 to $145 million in FY25. The company has reached a scale where it's expected to become free cash flow positive in FY26, which would also allow it to achieve the Rule of 40 for the first time, with revenue growth of 20% or more and an underlying EBITDA margin above 20%.

On 4 November, three Non-Executive Directors sold a collective $4.6 million worth of shares at 75 cents apiece. At face value, it doesn't look good. However, none of the directors sold previous holdings. They exercised options and sold the resulting shares on market. These short-term options convert into one share for no consideration, subject to various milestones including budgeted cash flow, EBITDA, ARR and job performance. All three Non-Executive Directors have been with the company for more than three years.

Qoria is now in the midst of a sharp pullback, down around 23% from its 21 October record high of 94 cents. The broader software sector is facing similar weakness, with names like Pro Medicus, TechnologyOne and Life360 all pulling back sharply from recent record highs.

Qoria (blue) vs. Life360 (yellow), TechnologyOne (green) and Pro Medicus (red) | (Source: TradingView)